The company states in NT 10-Q filing: “As previously disclosed by the Company, including in its Quarterly Report on Form 10-Q for the quarter ended June 3, 2023, filed with the U.S. Securities and Exchange Commission on July 11, 2023, the Company has been engaged in reviewing and continues to review strategic alternatives to recapitalize, refinance or otherwise optimize its capital structure, which may ultimately result in the Company pursuing one or more significant corporate transactions or other remedial measures. As part of the preparation of the Form 10-Q, the Company is conducting an impairment charge analysis, which, together with the processes involved in the Ongoing Review, require significant resources from the Company’s financial, accounting and administrative personnel. As a result, the Company is unable to complete and file the Form 10-Q by the prescribed due date without unreasonable effort and expense.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RAD:
- Unusually active option classes on open October 11th
- Largest borrow rate increases among liquid names
- Rite Aid price target lowered to $0 from $1 at Evercore ISI
- Rite Aid receives noncompliance notification from Nasdaq
- Novavax Stock (NASDAQ:NVAX) Surged After Winning the FDA’s Approval
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue